$55.85
+0.93 (+1.69%)
Open$55.21
Previous Close$54.92
Day High$55.88
Day Low$54.60
52W High$72.36
52W Low$12.98
Volume—
Avg Volume501.9K
Market Cap1.63B
P/E Ratio—
EPS$-0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
-7.3% upside
Current
$55.85
$55.85
Target
$51.79
$51.79
$39.42
$51.79 avg
$66.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 240.93M | 82.73M | 183.45M |
| Net Income | -13,588,310 | -118,469,876 | 2.09M |
| Profit Margin | -5.6% | -151.2% | 1.1% |
| EBITDA | 49.76M | -141,571,926 | 3.06M |
| Free Cash Flow | — | — | 1.04M |
| Rev Growth | +183.6% | +13.1% | +5.3% |
| Debt/Equity | 7.43 | 4.99 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |